Table 1– Patient characteristics
CharacteristicTrial
ELCWP 1922 [9]ELCWP 1923 [8]ELCWP 1994All ELCWP trialsPaesmans et al. [4]Sculier et al. [2]
Subjects2042332566937636609
Sex
 Male163 (80)196 (84)211 (82)570 (82)689 (90)4368 (66)
  Female41 (20)37 (16)45 (18)123 (18)74 (10)2241 (34)
Age yrs59 (32–75)61 (34–74)61 (40–83)60 (32–84)NRNR
Karnofsky performance status
 60–7014 (7)57 (24)64 (25)135 (19)250 (33)1409 (21)
 80–90190 (93)176 (76)192 (75)558 (81)513 (67)5200 (79)
 10088 (43)41 (18)31 (12)160 (23)NR2039 (31)
Disease extent
 Limited204 (100)18 (8)16 (6)238 (34)365 (48)2870 (43)
  Very limited20410205NRNR
 Extensive215 (92)240 (94)455 (66)398 (52)3739 (57)
  >2 metastatic sites305383NRNR
Pleural effusion
 Not documented204 (100)200 (86)219 (86)623 (90)NRNR
 Yes33 (14)37 (14)70 (10)
White blood cell count
 <10 IU152 (75)155 (67)153 (60)460 (66)516NR
 ≥10 IU52 (25)78 (33)100 (39)230 (33)241
 Not reported3 (1)3 (<1)6
Relative neutrophil count
 ≤75%166 (81)154 (66)152 (59)472 (68)528 (69)NR
 >75%35 (17)74 (32)68 (27)177 (26)212 (28)
 NR3 (1)5 (2)36 (14)44 (6)23 (3)
Alkaline phosphatases
 Normal101 (50)69 (30)107 (42)277 (40)297NR
 Abnormal77 (38)158 (68)144 (56)379 (55)431
 NR26 (13)6 (3)5 (2)37 (5)35
Creatinine
 Normal199 (98)225 (97)249 (97)673 (97)NRNR
 Abnormal3 (1)6 (3)4 (2)13 (2)
 NR2 (1)2 (1)3 (1)7 (1)
LDH
 Normal144 (71)123 (53)127 (50)394 (57)NRNR
 Abnormal30 (15)88 (38)98 (38)216 (31)
 NR30 (15)22 (9)31 (12)83 (12)
  • Data are presented as n, n (%) or median (range). ELCWP: European Lung Cancer Working Party; NR: not reported; LDH: lactate dehydrogenase.